Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Clinical Oncology 4, 394–395 (1 July 2007) | doi:10.1038/ncponc0847
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
&
Abstract
Attal M et al. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289–3294 Synopsis Background Almost all patients with multiple myeloma who receive conventional chemotherapy with autologous stem cell transplantation relapse, most within 3 years.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
